Savara rises as UK accepts application for rare lung disease drug

Savara

07/04/2026 13:46

** Shares of biotech firm Savara SVRA.O rise 2% to $5.70 premarket

** Co says UK drug regulator has accepted application for Molbreevi to treat autoimmune pulmonary alveolar proteinosis

** The rare lung disease causes a build-up of material in the air sacs, making it hard for patients to breathe

** UK regulator will review the drug under an accelerated process, with a decision expected in Q4 2026, co says

** Says Molbreevi is an inhaled drug designed to help the lungs clear the build-up

** Reviews of the drug are also underway in the U.S. and Europe, with FDA action due in August 2026 and EU decision expected in Q1 2027, co says

** As of last close, stock down ~7% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))